Roche asks FDA not to limit proposal on hypnotic relabeling and repackaging to benzodiazepines in a Jan. 15 letter to the agency's Neuropharmacological Drugs Division. Roche, which manufactures Dalmane, was among the companies receiving a Dec. 3 letter from FDA Neuropharmacological Drugs Division Director Paul Leber, MD, asking for relabeling, repackaging, and patient package inserts for all benzodiazepines on the model adopted for Upjohn's Halcion ("The Pink Sheet" Dec. 16, T&G-1). Roche said it also asked FDA to take steps to ensure that all hypnotic manufacturers comply with the agency's request at the same time. In addition, Roche said it expressed its concern that differences between benzodiazepine products, such as half-life and incidence of specific side effects, would be obscured by class labeling....
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth